BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 10084288)

  • 1. Strategies for iron supplementation: oral versus intravenous.
    Macdougall IC
    Kidney Int Suppl; 1999 Mar; 69():S61-6. PubMed ID: 10084288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron status and iron supplementation in peritoneal dialysis patients.
    Vychytil A; Haag-Weber M
    Kidney Int Suppl; 1999 Mar; 69():S71-8. PubMed ID: 10084290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin hyporesponsiveness: from iron deficiency to iron overload.
    Tarng DC; Huang TP; Chen TW; Yang WC
    Kidney Int Suppl; 1999 Mar; 69():S107-18. PubMed ID: 10084294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron monitoring and supplementation: how do we achieve the best results?
    Schaefer RM; Schaefer L
    Nephrol Dial Transplant; 1998; 13 Suppl 2():9-12. PubMed ID: 9566484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
    Frankenfield DL; Johnson CA
    Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective open-label study evaluating the efficacy and adverse reactions of the use of Niferex-150 in ESRD patients receiving EPOGEN.
    Johnson CA; Rosowski E; Zimmerman SW
    Adv Perit Dial; 1992; 8():444-7. PubMed ID: 1361844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
    Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
    Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
    Taylor JE; Peat N; Porter C; Morgan AG
    Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of iron indices in hemodialysis patients receiving epoetin.
    Kaufman JS; Reda DJ; Fye CL; Goldfarb DS; Henderson WG; Kleinman JG; Vaamonde CA;
    Kidney Int; 2001 Jul; 60(1):300-8. PubMed ID: 11422765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
    Riedel MK; Morgenstern T
    Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin.
    Wingard RL; Parker RA; Ismail N; Hakim RM
    Am J Kidney Dis; 1995 Mar; 25(3):433-9. PubMed ID: 7872321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous iron for the treatment of predialysis anemia.
    Silverberg DS; Blum M; Agbaria Z; Schwartz D; Zubkov A; Yachnin T; Iaina A
    Kidney Int Suppl; 1999 Mar; 69():S79-85. PubMed ID: 10084291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous iron dextran and erythropoietin use in pediatric hemodialysis patients.
    Greenbaum LA; Pan CG; Caley C; Nelson T; Sheth KJ
    Pediatr Nephrol; 2000 Sep; 14(10-11):908-11. PubMed ID: 10975297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Considerations for optimal iron use for anemia due to chronic kidney disease.
    Hudson JQ; Comstock TJ
    Clin Ther; 2001 Oct; 23(10):1637-71. PubMed ID: 11726002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of intravenous injection of iron saccharate in haemodialysis patients.
    Sunder-Plassmann G; Hörl WH
    Nephrol Dial Transplant; 1996 Sep; 11(9):1797-802. PubMed ID: 8918625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients.
    Nissenson AR; Berns JS; Sakiewicz P; Ghaddar S; Moore GM; Schleicher RB; Seligman PA
    Am J Kidney Dis; 2003 Aug; 42(2):325-30. PubMed ID: 12900815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hypochromic red cell: a new parameter for monitoring of iron supplementation during rhEPO therapy.
    Schaefer RM; Schaefer L
    J Perinat Med; 1995; 23(1-2):83-8. PubMed ID: 7658326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial ferritin concentrations in hemodialysis patients receiving intravenous iron.
    Kirschbaum B
    Clin Nephrol; 2002 Jun; 57(6):452-6. PubMed ID: 12078949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
    McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ
    Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive vision for intravenous iron therapy.
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.